To develop a framework that will provide methodologies to prioritise new and existing medicinal compounds for a comprehensive environmental risk assessment.
1) To review of existing approaches for prioritization of APIs and their intelligent testing based on mode of action and to develop improved frameworks for such purposes, 2) To establish a high-quality database on the properties, environmental fate characteristics and ecotoxicity of APIs, 3) To develop methods for estimating external and internal exposure to APIs for different scenarios, 4) To develop methods and models for predicting ecotoxicological responses to APIs, 5) To validate the developed models, concepts and frameworks using targeted experiments, 6) To develop a software system to support intelligent testing and prioritization of APIs in the environment, 7) To develop guidance on how the software system and associated predictive tools can be used, 8) To engage with and exchange knowledge with stakeholder groups throughout the project.
- A review of the pharmaceutical exposome in aquatic fauna
- Intelligence-led Assessment of Pharmaceuticals in the Environment
- Intelligence-led Assessment of Pharmaceuticals in the Environment
- Intelligence-led Assessment of Pharmaceuticals in the Environment
- Temporal and spatial variation in pharmaceutical concentrations in an urban river system
- ECOdrug
- ECOdrug: a database connecting drugs and conservation of their targets across species
- Exposure to Pharmaceuticals in the Environment – ePiE technical model description
- IMI1 Final Project Report Public Summary
HCWH Europe gratefully acknowledges the financial support of the European Commission (EC)’s LIFE+ programme, the Federal Ministry for the Environment, Nature Conservation, and Nuclear Safety (BMU) Germany, and the German Environment Agency (UBA). HCWH Europe is solely responsible for the content of this project and related materials. The views expressed do not reflect the official views of the EC, BMU, or UBA.
